6 results in Exploration of Targeted Anti-tumor Therapy
Latest
Sort by :
- Latest
- Most Viewed
- Most Downloaded
- Most Cited
Open Access
Review
Novel approaches for the rational design of PROTAC linkers
Almaz Zagidullin ... Emil Bulatov
Published: October 30, 2020 Explor Target Antitumor Ther. 2020;1:381–390
This article belongs to the special issue Proteolysis Targeting Chimera (PROTAC)
Open Access
Review
Potential of guggulsterone, a farnesoid X receptor antagonist, in the prevention and treatment of cancer
Sosmitha Girisa ... Ajaikumar B. Kunnumakkara
Published: October 30, 2020 Explor Target Antitumor Ther. 2020;1:313–342
This article belongs to the special issue Targeting Transcription Factors for Cancer Therapy
Open Access
Case Report
Pseudoprogression in lung cancer: a case report
Giulia Meoni ... Angela Stefania Ribecco
Published: October 30, 2020 Explor Target Antitumor Ther. 2020;1:372–380
This article belongs to the special issue Immunotherapy in Cancer Patients
Open Access
Original Article
Downregulation of 15-hydroxyprostaglandin dehydrogenase during acquired tamoxifen resistance and association with poor prognosis in ERα-positive breast cancer
Milene Volpato ... Valerie Speirs
Published: October 30, 2020 Explor Target Antitumor Ther. 2020;1:355–371
Open Access
Review
Current strategies for the design of PROTAC linkers: a critical review
Robert I. Troup ... Matthias G. J. Baud
Published: October 30, 2020 Explor Target Antitumor Ther. 2020;1:273–312
This article belongs to the special issue Proteolysis Targeting Chimera (PROTAC)
Open Access
Review
Diagnostic and prognostic role of liquid biopsy in non-small cell lung cancer: evaluation of circulating biomarkers
Giovanni Vicidomini ... Mario Santini
Published: October 30, 2020 Explor Target Antitumor Ther. 2020;1:343–354
This article belongs to the special issue Liquid Biopsy in Thoracic Cancer
Previous